SWOG/Hope Foundation Impact Awards
All Grants Awarded

2023
Lisa M. Rimsza, MD, Mayo Clinic in Arizona
“Prediction of Early Progression of Disease in Follicular Lymphoma”

2022
Abdul Rafeh Naqash, MD, University of Oklahoma Health Stephenson Cancer Center
“Multi-omics characterization of the immune landscape and metabolic vulnerabilities in alveolar soft part sarcoma to optimize therapeutic strategies using novel immune-oncology-based approaches”

Derek L. Stirewalt, MD, and Megan Othus, PhD, Fred Hutchinson Cancer Center
“Development of Innovative Approaches to Risk Stratify and Target Therapy for AML”

2021
Kerryn Reding, PhD, MPH, RN, University of Washington School of Nursing
“Cecebot: A Personalized, SMS-Based Conversational Agent to Address Sleep Disturbance in Women with Poor Sleep After Breast Cancer Treatment”

Katherine Crew, MD, MS, Columbia University Irving Medical Center
“Application of a convolutional neural network-based model to breast imaging to assess prognosis and predict response to adjuvant breast cancer treatment”

Rajshekhar Chakraborty, MD, Columbia University Irving Medical Center
“Non-Invasive Minimal Residual Disease Assessment in Multiple Myeloma with Liquid Biopsy and Functional Imaging”

2020
George V. Thomas, MD, Oregon Health & Science University
“Developing Novel Polytherapies for Non-Clear Cell Renal Carcinoma”

2019
Corey Speers, MD, PhD, and James Rae, PhD, University of Michigan
“Derivation of endocrine and chemotherapy resistance gene signatures and evaluation of previously developed molecular signatures as prognostic and predictive biomarkers in SWOG 8814”

Shing Lee, PhD, Columbia University & Joseph Unger, PhD, Fred Hutchinson Cancer Research Center
“Analysis and visualization of adverse events and patient-reported outcomes that reflect overall treatment toxicity burden”
<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Affiliation</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Richard Burack, MD, PhD</td>
<td>University of Rochester Medical Center</td>
<td>“Targeting TP53 with radioimmunotherapy in lymphoma”</td>
</tr>
<tr>
<td></td>
<td>Brian Shuch, MD</td>
<td>University of California, Los Angeles</td>
<td>“Identification and Characterization of Oncometabolite-Induced DNA Repair Defects in Sporadic Papillary Kidney Cancer”</td>
</tr>
<tr>
<td></td>
<td>Austin Kirschner, MD</td>
<td>Vanderbilt University Medical Center</td>
<td>“Immuno-PET imaging as a predictive biomarker for immune-radiotherapy for metastatic castration-resistant prostate cancer”</td>
</tr>
<tr>
<td>2017</td>
<td>Irene Tami-Maury, DMD, MSc, DrPH</td>
<td>MD Anderson Cancer Center</td>
<td>“STOP, SWOG Tobacco Program for the Oncology Practice”</td>
</tr>
<tr>
<td>2016</td>
<td>Yi-Fen Lee, PhD &amp; Edward M. Messing, MD</td>
<td>University of Rochester</td>
<td>“Extracellular Vesicle Biomarkers for Predicting Response to BCG Therapy”</td>
</tr>
<tr>
<td></td>
<td>Joshi J. Alumkal, MD</td>
<td>Oregon Health &amp; Science University</td>
<td>“Targeting AR-Independent Mechanisms of Prostate Cancer Progression with BET Bromodin Inhibition”</td>
</tr>
<tr>
<td></td>
<td>Michael W. Deininger, MD, PhD</td>
<td>University of Utah Huntsman Cancer Institute</td>
<td>“Targeting Nuclear-Cytoplasmic Transport in Myelofibrosis”</td>
</tr>
<tr>
<td></td>
<td>Eduardo Vilar Sanchez, MD, PhD</td>
<td>MD Anderson Cancer Center</td>
<td>“Sulindac plus Bexarotene for Chemoprevention of Colorectal Polyps”</td>
</tr>
<tr>
<td>2015</td>
<td>Daruka Mahadevan, MD, PhD</td>
<td>University of Arizona</td>
<td>“Aurora plus PI3K Inhibition Abrogates PD-L1 Induction in Nodal T-cell Lymphoma”</td>
</tr>
<tr>
<td></td>
<td>Catharine L. Smith, PhD</td>
<td>University of Arizona</td>
<td>“Identifying Biomarkers of Sensitivity to Histone Deacetylase Inhibitors in DLBCL”</td>
</tr>
<tr>
<td></td>
<td>Marc Loriaux, MD, PhD</td>
<td>Oregon Health &amp; Science University</td>
<td>“Personalizing treatment for newly diagnosed AML using a novel ex vivo screen”</td>
</tr>
<tr>
<td>2014</td>
<td>Kevin Kalinsky, MD, MS</td>
<td>Columbia University Cancer Center</td>
<td>“Master regulator analysis to prioritize testing of patient-derived xenografts to identify effective precision treatments for patients with residual disease after neoadjuvant breast cancer chemotherapy”</td>
</tr>
<tr>
<td></td>
<td>Scott Kopetz, MD, PhD</td>
<td>MD Anderson Cancer Center</td>
<td></td>
</tr>
</tbody>
</table>
“Patient-derived xenografts as a model for treatment efficacy and resistance mechanisms in a matched prospective clinical trial: SWOG S1406 for BRAF-mutated metastatic colorectal cancer”

Roger Lo, MD, PhD and Antoni Ribas, MD, PhD, University of California, Los Angeles
“Combined BRAF/AKT Inhibition to Reverse Melanoma Resistance to MAPK Inhibition”

2013

Robert Doebele, MD, University of Colorado
“Evaluation of crizotinib resistance mechanisms to predict pemetrexed sensitivity”

Omar Aljitawi, MD, University of Kansas Medical Center
“Pilot study exploring the use of hyperbaric oxygen in autologous PBSC transplantation”

2012

Mikala Egeblad, PhD, Cold Spring Harbor Laboratory
"Real-time response to bevacizumab and cytotoxic therapy"

Matthew Maurer, MD, Columbia University
"CSI-Lethality: a novel strategy for cancer therapeutic target discovery"

Roland B. Walter, MD, PhD, Fred Hutchinson Cancer Research Center
"Prognostic and Therapeutic Significance of Stem Cell Heterogeneity in AML"

Vivian Oehler, MD, Fred Hutchinson Cancer Research Center
“Aberrant Myeloid Differentiation and MicroRNA Regulation in Acute Leukemia”

Monika Schmelz, PhD, University of Arizona Cancer Center
“Mechanisms for Immune Escape in Aggressive Lymphoma with Poor Survival”

2011

Min Fang, MD, PhD, Fred Hutchinson Cancer Research Center
“Identification of Differently Methylated Genomic Regions That Are Prognostically Significant in AML”

Manual Valdivieso, MD, University of Michigan
“The Role of Contaminated Water in H. pylori”

Dawn Hershman, MD, Columbia University & John Crowley, PhD, Cancer Research And Biostatistics
“Obtaining Medicare Claims Data for Use in SWOG Comparative Effectiveness Studies”

R. Eric Davis, MD, MD Anderson Cancer Center
“Developing Combination Chemotherapy and Targeting Resistance in B-Cell Lymphoma”

Daruka Mahadevan, MD, University of Tennessee Health Science Center
“Novel Aurora plus Bruton’s Tyrosine Kinase Targeted Therapies for Aggressive B-cell non-Hodgkin’s Lymphoma”

George V. Thomas, MD, Oregon Health & Science University
"Inhibiting Src in VHL-Positive Renal Cell Carcinoma"
Robert Krouse, MD, University of Arizona Cancer Center
"Prospective Validation of Karyometric Analysis: Cutaneous Squamous Cell Carcinoma"

Updated June 2023